© Reuters.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) director John P. Schmid has recently increased his stake in the company, purchasing additional shares valued at a total of $9,720. The transaction took place on March 14, as indicated by the latest filings with the Securities and Exchange Commission.
Schmid acquired 4,500 shares of common stock at a price of $2.16 per share. Following this transaction, the total number of shares owned by Schmid is reported to be 11,000, which are held indirectly by The Schmid Family Trust, as per the footnotes in the filing. The director disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
This recent purchase by a member of the company’s board is a move that investors often watch closely, as it can be indicative of the director’s confidence in the future of the company.
Xeris Biopharma Holdings is a pharmaceutical company based in Chicago, Illinois, specializing in pharmaceutical preparations. As of the date of the report, the company has not issued any statements regarding the transaction.
Investors and market watchers typically keep an eye on insider transactions as they provide insights into how the top brass at the company are viewing the stock’s value and potential.
The stock of Xeris Biopharma Holdings, Inc. is publicly traded on the NASDAQ stock exchange under the ticker symbol XERS.
InvestingPro Insights
As Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) experiences insider activity with director John P. Schmid increasing his stake in the company, market participants are evaluating the company’s financial health and future prospects. With a current market capitalization of $299.17 million, Xeris Biopharma’s position in the pharmaceutical industry is under scrutiny, especially with recent performance data and analyst insights from InvestingPro.
InvestingPro Data indicates that Xeris Biopharma has a negative Price/Earnings (P/E) ratio of -4.58 for the last twelve months as of Q4 2023, reflecting the market’s sentiment about the company’s earnings. Despite a notable revenue growth of 48.68% during the same period, the company’s operating income margin stood at -26.85%, indicating challenges in converting revenues to operating income.
InvestingPro Tips suggest caution, as the company’s stock is currently in oversold territory according to the Relative Strength Index (RSI), and analysts have revised their earnings expectations downwards for the upcoming period. Furthermore, while the stock has experienced a high return over the last year, with a 63.85% price total return, it has fared poorly over the last month, showing a -33.64% return. These metrics may provide context to the director’s recent share purchase, potentially viewing the current valuation as an opportunity.
For those looking to delve deeper into the financials and forecasts for Xeris Biopharma Holdings, Inc., there are additional InvestingPro Tips available. These include insights on the company’s cash burn rate, profitability outlook, and dividend policy. To explore these further, investors can access a wealth of information on InvestingPro. Moreover, for a limited time, users can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, providing even more value to those seeking comprehensive investment analysis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here
